Home > News > Detailed Positive ABRAXANE Phase III Data Released
December 8th, 2003
Detailed Positive ABRAXANE Phase III Data Released
American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the CremophorŽ solvent-based TAXOLŽ. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOLŽ.
UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique: Oil-and-water approach from Richmond's UO lab to spark new line of versatile peptoid nanosheets September 2nd, 2014
Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014
Nano-forests to reveal secrets of cells September 2nd, 2014
Nanoscale assembly line August 29th, 2014